Yahoo
NYSE - Delayed Quote USD

Inspire Medical Systems, Inc. (INSP)

68.10 -3.08 (-4.33%)
At close: October 30 at 4:00:03 PM EDT
68.10 0.00 (0.00%)
After hours: October 30 at 5:05:00 PM EDT
Trade INSP on Coinbase
INSP Q3 2026 earnings call
November 2, 2026 at 5 PM EST
Chart Range Bar
Loading chart for INSP
  • Previous Close 71.18
  • Open 70.63
  • Bid 68.12 x 20000
  • Ask 68.32 x 20000
  • Day's Range 67.80 - 71.19
  • 52 Week Range 38.91 - 147.03
  • Volume 796,362
  • Avg. Volume 774,848
  • Market Cap (intraday) 1.969B
  • Beta (5Y Monthly) 0.73
  • PE Ratio (TTM) 15.00
  • EPS (TTM) 4.54
  • Earnings Date Nov 2, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 68.00
  • Zacks Rating Bearish

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

www.inspiresleep.com

1,333

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

INSP
26.16%
S&P 500 (^GSPC)
10.73%

1-Year Return

INSP
6.80%
S&P 500 (^GSPC)
11.11%

3-Year Return

INSP
53.30%
S&P 500 (^GSPC)
81.91%

5-Year Return

INSP
74.74%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 200.58M
Earnings 314k
Profit Margin 0.16%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
50M
100M
150M
200M
250M
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%

Analyst Insights

View More

Analyst Price Targets

40.00 Low
68.00 Average
68.10 Current
97.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/14/2026
Analyst Truist Securities
Rating Action Maintains
Rating Hold
Price Action Raises
Price Target 62 -> 78

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    15.03%

  • Return on Assets (ttm)

    3.91%

  • Return on Equity (ttm)

    17.97%

  • Revenue (ttm)

    898.74M

  • Net Income Avi to Common (ttm)

    135.04M

  • Diluted EPS (ttm)

    4.54

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    320.68M

  • Total Debt/Equity (mrq)

    3.52%

  • Levered Free Cash Flow (ttm)

    94.64M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: